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Abstract
Background: Bone turnover markers are useful to evaluate bone loss and 
monitor anticatabolic treatments in a short period. The effectiveness of saliva 
to reflect changes in bone turnover markers during the early administration 
of different doses of olpadronate (POD) (4 mg or 8 mg/100 g body weight), 
immediately after Ovariectomy (OVX), was Evaluated. 
Material and Methods: Adult rats (n=10/group) were divided and treated 
as follows for 45 days: SHAM+Vh; OVX+Vh; OVX+4OPD and OVX+8OPD. 
To validate the model, Proximal Tibia Bone Mineral Density (PTBMD) change 
between the beginning and the end of the study. Blood and saliva were collected 
post-surgery (t=0; t=10; t=20; t=45). 
Results: PTBMD decrease in OVX+Vh was partially prevented by 4OPD 
and avoided by 8OPD. Salivary and serum β-CrossLaps (CTX) in SHAM+Vh 
remained without changes and increased in OVX+Vh (p<0.05); Bone-Specific 
Alkaline Phosphatase (B-ALP) increased in OVX+Vh versus SHAM+Vh reaching 
signicance at t=20 (p< 0.05). A dose-dependent response was observed in 
salivary and serum CTX and B-ALP by OPD treatment (p<0.05). CTX was lower 
in OVX+8OPD versus OVX+4OPD from t=10 in serum samples and from t=20 
in salivary samples (p<0.05) while B-ALP reached lower levels at t=45 (p<0.05). 
Conclusion: Although further clinical studies are needed, our results 
suggest that CTX and B-ALP in saliva decreased by Bisphosphonate (BP) 
therapy in a dose dependent manner. Therefore, saliva would be a suitable tool 
for evaluating changes in bone turnover due to BP therapy in the early stage of 
estrogen withdrawal. 
Keywords: Bone Turnover Markers; Osteoporosis; Saliva; Estrogen 
Withdrawal; Bisphosphonates
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Introduction
The decline in estradiol levels that follow menopausal transition 
and early menopause bone is a dynamic and metabolically active 
tissue that is continuously remodeling by the coordinated actions 
of osteoclasts and osteoblasts in cellular packages called Bone 
Remodeling Units (BMUs) [1]. The whole process of bone remodeling 
is a cycle, which begins with the resorption of old bone by the action 
of the osteoclasts, followed by the formation of new bone tissue 
by osteoblasts. The resorption phase lasts approximately 12 days; 
however, the formation phase is a slower process lasting 3 months. As 
bone resorption is faster than bone formation, every increase in bone 
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turnover is characterized by bone loss [2].
The decline in estradiol levels that follow menopausal transition 
and early menopause state induces a dramatic increase in bone 
remodeling that leads to an accelerated bone loss increasing the risk 
of osteopenia/osteoporosis [3]. 
The most commonly experimental model used to evaluate the loss 
of bone link to estrogen deficiency is the ovariectomized rat [4]. In 
this sense, it has been shown that the OVX rat exhibits an accelerated 
bone turnover with a higher increase in bone resorption than bone 
formation, as well as, trabecular bone loss [5].
Bisphosphonates (BPs) are anticatabolic drugs widely used 
as the first treatment of choice to reduce the fast bone loss caused 
by osteopenia/osteoporosis due to their potency to suppress bone 
remodeling [6]. 
Bone remodeling levels can be assessed by measuring biochemical 
bone turnover markers of bone formation and resorption. Bone 
turnover markers are useful tool to evaluate the rate of bone loss in 
postmenopausal women as occur in osteoporosis and other metabolic 
bone diseases [7,8]. In addition, they are suitable to monitor the 
efficacy of an anticatabolic treatment in a short period of time. Even 
though bone turnover markers are usually evaluated in blood and 
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urine samples, it has been shown that they can also be measured in 
saliva samples [7-10].
The use of saliva as a biological sample presents many advantages 
due to its fast, easy and inexpensive collection. In addition, as the 
collection of saliva is not invasive, samples are appropriate for home 
use since it does not require the presence of medical personnel [11].
The present longitudinal experimental study aims to evaluate 
the effectiveness of saliva as compared to serum samples to reflect 
changes in bone turnover markers induced by the treatment with two 
different doses of Olpadronate (OPD) immediately after estrogen 
withdrawal induced by Ovariectomy (OVX).
Material and Methods
Drugs
The aminobisphosphonate OPD was kindly provided by GADOR 
(S.A, Argentina) as two saline solutions (3.2 or 6.4 mg/100 mL). 
The low and high doses of OPD were in keeping with previous 
experimental dose-response studies [12]. Ketamine hydrochloride 
(Holliday-Scott, Buenos Aires, Argentina) and acepromazine maleate 
(0.1 mg each/100 g body weight), were used as light anesthesia. 
Salivation was stimulated by intraperitoneal injection of pilocarpine 
1% (Alcon Argentine laboratories) in a dose of 0.2 mg pilocarpine 
hydrochloride/100 g body weight. All drugs were administered 
intraperitoneally.
Animals and experimental design
Forty female, virgin, adult Wistar rats (250 to 300 g) were 
housed at room temperature (21ºC ± 1ºC) with 55% ± 10% humidity 
under 12-hour light/dark cycles; they were fed standard rodent diet 
(Granave, Argentina) and deionized water ad libitum. Body weight 
was recorded weekly. The rats were maintained in keeping with 
the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals [13]. 
After 1 week of acclimatization, 10 animals were SHAM surgery, 
and the remaining 30 rats were subjected to bilateral OVX. Two days 
post-surgery, the animals were divided into four groups and treated 
as follows for 45 days:
SHAM+Vh = SHAM+ vehicle (saline solution); 
OVX+Vh = OVX+ vehicle (saline solution);
OVX+4OPD= OVX+ 4 mg OPD/100 g body weight; 
OVX+8OPD = OVX+ 8 mg OPD/100 g body weight; 
The study was approved by the Buenos Aires University 
Institutional Review Board.
Bone mineral density
To validate the experimental model, all animals were subjected 
to a densitometric analysis ‘‘in vivo’’ by dual energy X-Ray 
Absorptiometry (DXA) under light anesthesia (0.1 mg ketamine 
hydrochloride/100 g body weight and 0.1 mg acetopromazine 
maleate/100 g weight). A whole body scanner and software designed 
specifically for small animals (DPX Alpha, Small Animal Software, 
Lunar Radiation Corp, Madison WI) were used as described in a 
previous report [14]. Briefly, all rats were scanned using an identical 
scanning procedure. Precision was assessed by measuring one rat five 
times, repositioning between scans, on the same day and on different 
days [15]. To evaluate the outcomes of the treatment, proximal tibia 
Bone Mineral Density (BMD) area was analyzed on the image of 
the animal on the screen using a Region of Interest (ROI) for the 
segment. The Variation Coefficient (VC) was 3.5% for proximal tibia. 
The changes in Proximal Tibia (PT) BMD between the end (t=45) and 
the beginning of the experience were calculated as a percentage of the 
baseline (t=0) BMD value.
Biochemical determinations
Fasting blood and saliva samples were collected at the onset of 
treatment and after each 10 days until the end of the experience [t=0 
(baseline); t=10; t=20 post surgery and at t=45]. Blood was obtained 
from the tail under ethyl ether anesthesia; the serum was separated 
and kept frozen at -20ºC until the analyses were performed. Collection 
of saliva was done 5 minutes post-stimulation for 1-minute period 
by using a sterile syringe. Saliva was centrifuged at 3.000xg for 10 
minutes to separate cells and large macromolecules. The supernatants 
were collected and frozen at -20ºC until the studies were performed.
All biochemical determinations were performed at the same time 
to avoid inter-assay variations. β-Cross Laps (CTX) levels (ng/mL) 
were measured using an enzyme-linked immunosorbent assay (Rat 
Laps, Osteometer BioTech, Herlev, Denmark) with a 6% intra-assay 
VC and a detection limit of 2.5 ng/mL [15]. Bone-Specific Alkaline 
Phosphatase (B-ALP) was measured using a colorimetric method 
after bone enzyme isoform precipitation with wheat germ lectin [15] 
(Boehringer Mannheim, Germany).
Statistical analysis
Results are expressed as mean ± Standard Deviation (SD). Data 
was Analyzed Using One-Way Analysis Of Variance (ANOVA). The 
Bonferroni multiple comparisons test was performed when significant 
differences were encountered. Statistical analyses were performed 
using a software package. p <0.05 was considered significant. 
Results
Model validation
As expected, SHAM+Vh group exhibited a slight change in 
PTBMD, whereas animals in the OVX+Vh group lost approximately 
20% of their PTBMD (Figure 1). OPD treatment decreased the loss of 
PTBMD in a dose-dependent manner. Indeed, treatment with 4 mg 
of OPD partially prevented the decrease in PTBMD while treatment 
with 8 mg of OPD avoided the decrease (Figure 1).
Bone turnover markers levels evaluated in saliva and 
serum presented a similar pattern of changes
No differences in baseline values of CTX and B-ALP in both, 
saliva and serum samples were observed. (Figures 2A,2B) showed 
the longitudinal changes in salivary and serum CTX levels. A similar 
pattern of change for CTX was observed in salivary and serum samples. 
In both biological samples, CTX levels evaluated in the SHAM+Vh 
group remain without changes throughout the study. However, CTX 
levels increased significantly in the OVX+Vh group as compared to 
SHAM+Vh as a function of time from t=10 (p<0.05). (Figures 3A,3B) 
showed the longitudinal variations in salivary and serum B-ALP 
levels. Both samples showed a similar pattern of change. Although a 
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trend towards higher levels in B-ALP was observed in the OVX+Vh 
versus SHAM+Vh group since the first week after the OVX surgery, 
these levels did not reach statistical signicance until t=20 (p< 0.05). 
In agreement with the changes in BMD, a dose-dependent 
response was observed in CTX and B-ALP levels in salivary and 
serum samples by treatment with OPD (Figures 2,3). In both samples, 
CTX reached lower significant levels in OVX+4OPD, as compared 
to OVX+Vh group since t=20. Moreover, CTX levels in SHAM 
and OVX+4OPD group did not show statistical changes during the 
studied period. Levels of CTX in both samples were significantly lower 
in OVX+8OPD versus OVX+Vh since t=10 and versus SHAM group 
since t=20. When the two dosis of OPD were compared, the CTX levels 
in OVX+8OPD were significantly lower than in OVX+4OPD from 
t=10 in serum samples and from t=20 in salivary samples (p<0.05). 
Levels of B-ALP in saliva and serum decreased in OVX+4OPD group 
as compared to OVX+Vh group, reaching statistical significance at 
t=45 (p<0.05), while as compared to SHAM+Vh group these levels 
did not show differences througut the study (Figure 3). Salivary and 
serum B-ALP levels decrease in OVX+8 OPD as compared to both 
OVX+Vh and SHAM+Vh group since t=20 (p<0.05). When the two 
doses of OPD were compared, the salivary and serum B-ALP levels in 
OVX+8OPD reached higher significant levels than in OVX+4OPD at 
t=45 (p<0.05). 
Discussion
Bone homeostasis is maintained by a delicate balance between 
bone formation and bone resorption processes. On this regard, 
bone remodeling maintains the health in the skeleton affected by 
microfractures and fatigue and, by the damage caused by stress. This 
process occurs at the BMUs by the couple action of osteoclasts, bone 
resorptive cells and osteoblasts, bone forming cells. Nonetheless, 
since bone resorption is faster than bone formation, any increase 
in bone remodeling results in a negative bone balance at each BMU 
leading to an increase risk of bone fractures [16].
Although the diagnosis of osteoporosis can be made by BMD 
using DXA, the increased concentrations of specific bone markers are 
associated with an accelerated bone loss [17]. Indeed, bone turnover 
markers provide dynamic information related to changes in bone 
cells activity in a short period of time, while the changes in BMD take 
longer to occur. For this reason, they are a predictable tool to identify 
patients at high risk of bone loss and subsequent fractures.
Estrogen is an important regulator of bone homeostasis since it 
regulates the receptor activator of Nuclear Factor (NF)-kB-ligand 
(RANKL) receptor activator of NF-kB (RANK), and the soluble decoy 
receptor Osteoprotegerin (OPG) axis [18]. During the menopausal 
transition, estradiol levels decline but they show an accelerated fall 
in the early menopause. Several cross‐sectional studies indicate that 
the highest increase in bone turnover markers is observed during the 
menopausal transition and remained higher after menopause [19]. 
This is why menopausal transition and early menopause represent a 
window of opportunities to prevent the rapid bone loss and micro 
architectural damage to counteract osteoporosis in later years [20].
BPs are the first drug of choice to initiate an anticatabolic 
therapy to prevent the accelerated bone loss and preserve the 
integrity of bone structure [21]. BPs bind with high affinity to 
hydroxyapatite, predominantly at areas of high bone turnover. In 
the bone microenviroment nitrogen-containing BPs (amino-BPs) 
are internalized by the osteoclasts inhibiting the mevalonate pathway 
and therefore the osteoclast mediated bone resorption [6]. OPD is an 
amino-BP that shares the therapeutic and pharmacological properties 
of pamidronate and alendronate, inducing a rapid and prolonged 
suppression of bone resorption [22]. 
Figure 1: Changes in proximal tibia Bone Mineral Density (BMD). The 
percent change was calculated as BMD values at the end of the experiment 
(t=45) minus BMD values at the beginning of treatment (t=0). Bars represent 
mean ± SD (n=10 rats/group). *p< 0.05 versus SHAM+Vh group, ** p< 0.05 
versus OVX+Vh group, ***p < 0.05 versus OVX+4 OPD group, by one-way 
ANOVA and Bonferroni as a post hoc test.
Figure 2: Longitudinal changes of β-CrossLaps (CTX) in saliva (A) and serum (B) samples thought out the study in the four studied groups. SHAM+Vh, OVX+Vh, 
OVX+4 OPD and OVX+8 OPD groups. n=10 rats/group. Results were expressed as mean ± SD.*p<0.05 versus SHAM+Vh group by one-way ANOVA followed by 
multiple comparisons using Bonferroni post hoc test.
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Although BMD is used to diagnose osteoporosis, it has limitations 
to monitor treatment efficacy and compliance in a short period of 
time. Conversely, changes of specific and sensitive bone markers in 
response to antirresortive agents occur as early as 15 days to one 
month after treatment. In this regard, BPs treatments are associated 
with a decrease up to 50%-70% in CTX levels depending on the agent, 
dose and mode of administration [23]. Another clinical utility of 
bone turnover markers is the compliance for the specific treatment. A 
significant fall in bone markers after starting a treatment indicates not 
only efficiency but also a good adherence to therapy [24]. 
CTX is a very small molecular fragment (2900 daltons), product 
of the breakdown of type I collagen containing pyridinium cross-
link, which is cleaned by the kidney [25]. Currently, CTX is the most 
sensitive bone resorption marker to assess changes in bone turnover 
both, in catabolic or anticatabolic conditions such as estrogen 
withdrawn and BPs treatment. On the other hand, B-ALP is the 
bone-specific isoform of the serum enzyme alkaline phosphatase, 
found on the surface of osteoblasts. B-ALP is a glycoprotein that 
presents a half-life of 1–2 days in the circulation, providing a specific 
and reliable index of bone formation [26]. Indeed, levels of B-ALP 
increase significantly in menopause and continue thereafter for more 
than 20 years, decreasing rapidly after BPs treatment [27]. On this 
regard, the mechanism by which amino BPs like OPD inhibits B-ALP 
might be the result of a chelation of divalent cations since this enzyme 
is strongly activated by Mg2+ and has a requirement for Zn2+ [28].
Previous studies evaluated bone turnover markers in saliva with 
different results. Early studies conducted by our group demonstrated 
that that CTX and B-ALP can be evaluated in saliva samples. Both bone 
turnover markers in saliva samples exhibited a correlation with those 
evaluated in serum samples during estrogen repletion and depletion 
conditions, both in women and in osteopenic rats [9,10]. McGehee 
et al found that other bone markers can be evaluated in saliva. Their 
results demonstrated that there were a significant correlations between 
the bone markers deoxypyridinium and osteocalcin with age, body 
mass index, calcaneus T-scores suggesting that saliva could be used as 
a fluid sample for assessing bone remodelling [29]. A recent clinical 
study in postmenopausal osteoporotic and healthy non-osteoporotic 
females determined osteocalcin and CTX in stimulated saliva. This 
study failed to find any correlation between these two bone markers 
in saliva and serum concentrations or BMD [30]. 
The results of the present study demonstrate that the bone 
turnover markers CTX and B-ALP, evaluated in saliva samples, 
responded in the same fashion as serum samples to the decrease in 
bone turnover that follows anticatabolic treatment with different 
doses of the potent amino-BP OPD. In addition, like normally seen in 
serum, salivary bone turnover markers levels evidenced the changes 
that occurred later in BMD.
Therefore, the results of the present report suggest that the 
assessment of bone markers in saliva samples would become a valuable 
alternative to blood-borne samples in a wide variety of clinical settings 
such as compromised vein access, obesity, hemophilia, elderly people, 
those with stability problems or in field studies [29]. In these cases 
the use of saliva samples would be a rapid and less invasive collection 
method. 
In conclusion, although further clinical studies are needed, our 
results indicate that CTX and B-ALP assessment in saliva samples 
are able to detect changes in bone turnover due to BPs therapy in 
a dose depend manner. Therefore, saliva would be a suitable tool to 
evaluate changes in bone turnover due to BP therapy in the early stage 
of estrogen withdrawal.
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